P2RX3: P2X purinoceptor 3
Extracellular ATP-activated non-selective cation channel.
- Drugs that act on it: 2
- Approved: 1
- In phases 1 to 3: 1
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on P2RX3, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
| Gefapixant | Approved | Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Small molecule | AntagonistP2X purinoceptor 3 antagonist | 1 |
| Camlipixant | Phase 3 | GSK | Small molecule | AntagonistP2X purinoceptor 3 antagonist | 1 |
| A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M) | Camlipixant | Phase 2 | Recruiting | GlaxoSmithKline | Apr 9, 2026 |
| The Real-world Treatment Satisfaction by Gefapixiant in RCC | Gefapixant | Not applicable | Recruiting | Nagoya City University | Aug 7, 2024 |
- Cough0.54
- Aging0.32
- Stress urinary incontinence0.26
- Insomnia0.22
- Deep vein thrombosis0.20
- Overactive bladder0.09
- Cardiac arrhythmia0.09
- Endometriosis0.09
- Asthma0.08
- Gastroesophageal reflux disease0.08
- Osteoarthritis0.08
- Chronic interstitial cystitis0.08
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2998, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P56373, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets